DrugPatentWatch Database Preview
Nextwave Company Profile
» See Plans and Pricing
What is the competitive landscape for NEXTWAVE, and what generic alternatives to NEXTWAVE drugs are available?
NEXTWAVE has two approved drugs.
There are twelve US patents protecting NEXTWAVE drugs.
There are thirty-four patent family members on NEXTWAVE drugs in fourteen countries.
Drugs and US Patents for Nextwave
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-001 | Dec 4, 2015 | RX | Yes | No | 8,999,386 | Start Trial | Y | Start Trial | |||
Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-003 | Dec 4, 2015 | RX | Yes | Yes | 9,844,544 | Start Trial | Y | Start Trial | |||
Nextwave Pharms | QUILLICHEW ER | methylphenidate hydrochloride | TABLET, EXTENDED RELEASE, CHEWABLE;ORAL | 207960-003 | Dec 4, 2015 | RX | Yes | Yes | 8,287,903 | Start Trial | Y | Start Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for NEXTWAVE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Extended-release Oral Suspension | 5 mg/mL | ➤ Subscribe | 2013-08-02 |
International Patents for Nextwave Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
China | 102488652 | Start Trial |
South Korea | 20080108520 | Start Trial |
Australia | 2017202955 | Start Trial |
>Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.